AstraZeneca plc (AZN) Given “Buy” Rating at Deutsche Bank AG
Deutsche Bank AG restated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Wednesday morning. Deutsche Bank AG currently has a GBX 5,800 ($75.71) price objective on the biopharmaceutical company’s stock.
AZN has been the topic of a number of other research reports. Jefferies Group reaffirmed a hold rating on shares of AstraZeneca plc in a report on Monday, June 6th. Berenberg Bank set a GBX 5,550 ($72.44) price objective on AstraZeneca plc and gave the stock a buy rating in a report on Thursday, August 25th. HSBC reaffirmed a hold rating and set a GBX 4,240 ($55.35) price objective on shares of AstraZeneca plc in a report on Friday, June 17th. Citigroup Inc. reaffirmed a buy rating on shares of AstraZeneca plc in a report on Wednesday, July 27th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price objective on AstraZeneca plc and gave the stock a sell rating in a report on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Hold and an average price target of GBX 4,926.80 ($64.31).
Shares of AstraZeneca plc (LON:AZN) traded down 1.46% during mid-day trading on Wednesday, hitting GBX 5047.00. The company’s stock had a trading volume of 921,938 shares. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The company’s market cap is GBX 63.84 billion. The stock has a 50-day moving average of GBX 5,023.53 and a 200-day moving average of GBX 4,390.05.
The business also recently announced a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were issued a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.